The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
Better serving global partners and advancing healthcare innovation
Lupin Diagnostics will equip doctors with accurate diagnosis in the patient journey by leveraging innovative technologies
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
Novavax’ clinical development program reported no severe allergic reactions
Subscribe To Our Newsletter & Stay Updated
